摘要
目的 观察布地奈德混悬液雾化吸入治疗高嗜酸性粒细胞(EOS)慢性阻塞性肺疾病(简称慢阻肺)急性加重期患者的的临床疗效。方法 选择2020年5月至2021年5月在铜川矿务局中心医院呼吸科就诊的60例高EOS (血EOS≥2%)慢阻肺急性加重期患者作为研究对象,按照随机数表法分为A组和B组各30例,A组患者采取常规治疗,B组患者在此基础上给予布地奈德混悬液雾化吸入治疗,两组均治疗14 d。比较两组患者的治疗效果、症状改善时间及住院时间,并比较两组患者治疗前后的C反应蛋白(CRP)、降钙素原(PCT)、EOS及疾病严重程度(mMRC评分、CAT评分)。结果 B组患者的治疗总有效率为96.67%,明显高于A组的73.33%,差异具有统计学意义(P<0.05);治疗后,B组患者的咳嗽改善时间、咳痰改善时间、气急改善时间及住院时间分别为(3.42±1.12) d、(4.15±1.27) d、(2.31±0.62) d、(7.49±1.26) d,明显短于A组的(5.19±1.08) d、(5.81±1.19) d、(3.17±0.74) d、(10.53±1.72) d,差异均具有统计学意义(P<0.05);B组患者治疗后的CRP、PCT、EOS分别为(6.29±1.47) mg/L、(0.06±0.02) ng/L、(2.47±0.65)%,明显低于A组的(8.33±2.14) mg/L、(0.10±0.03) ng/L、(5.93±0.91)%,且m MRC评分及CAT评分分别为(0.68±0.21)分、(8.39±1.18)分,明显低于A组的(0.89±0.25)分、(9.51±2.12)分,差异均有统计学意义(P<0.05)。结论 布地奈德混悬液治疗高EOS慢阻肺急性加重期患者的疗效确切,可以明显改善患者症状,缩短住院时间,缓解炎症反应。
Objective To observe the clinical efficacy of aerosol inhalation of budesonide suspension in the treatment of patients with acute exacerbation of high eosinophil(EOS)chronic obstructive pulmonary disease(COPD).Methods A total of 60 patients with acute exacerbation of high EOS COPD(blood EOS count≥2%)who were treated in the Department of Respiratory Medicine,Tongchuan Mining Bureau Central Hospital from May 2020 to May 2021 were selected as the research subjects.They were divided into group A and group B by random number table method,with 30 cases in each group.Patients in the group A were given conventional treatment,and patients in the group B were treated with aerosol inhalation of budesonide suspension on the basis of group A,for 14 days.Curative effect,improvement time of symptoms,length of hospital stay,C-reactive protein(CRP),procalcitonin(PCT),EOS and disease severity(mMRC score and CAT score)were compared between the two groups.Results The total treatment response rate in the group B was 96.67%,which was significantly higher than 73.33%in the group A(P<0.05).After treatment,the cough improvement time,sputum improvement time,dyspnea improvement time,and length of hospital stay in the group B were(3.42±1.12)d,(4.15±1.27)d,(2.31±0.62)d,and(7.49±1.26)d,respectively,which were significantly shorter than(5.19±1.08)d,(5.81±1.19)d,(3.17±0.74)d,and(10.53±1.72)d in the group A(P<0.05).After treatment,the levels of CRP,PCT,and EOS in the group B were(6.29±1.47)mg/L,(0.06±0.02)ng/L,and(2.47±0.65)%,respectively,which were significantly lower than(8.33±2.14)mg/L,(0.10±0.03)ng/L,and(5.93±0.91)%in the group A,and the mMRC and CAT scores were(0.68±0.21)points and(8.39±1.18)points,significantly lower than(0.89±0.25)points and(9.51±2.12)points in the group A,with statistically significant differences(P<0.05).Conclusion Budesonide suspension is effectively in the treatment of patients with acute exacerbation of high EOS COPD,which can significantly relieve symptoms and shorten length of hospital stay,and
作者
张青
宋明
闫嘉
王娇
何彩秀
ZHANG Qing;SONG Ming;YAN Jia;WANG Jiao;HE Cai-xiu(Department of Respiratory Medicine,Tongchuan Mining Bureau Central Hospital,Tongchuan 727000,Shaanxi,CHINA)
出处
《海南医学》
CAS
2023年第14期1998-2001,共4页
Hainan Medical Journal
基金
陕西省重点研发计划项目(编号:2020SF-150)。
关键词
慢性阻塞性肺疾病
急性加重期
嗜酸性粒细胞
布地奈德
炎症因子
Chronic obstructive pulmonary disease
Acute exacerbation
Eosinophil
Budesonide
Inflammatory factors
